Exabis Library
Welcome to the e-CCO Library!
P547: Distribution of mesenteric macrophage polarisation: a guide for surgical resections in Crohn’s disease?
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P547: Early modification of inflammatory burden through treatment with vedolizumab or adalimumab is predictive of long-term treatment success in patients with Ulcerative Colitis from the VARSITY Study
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P547: Is there an association between bariatric surgery and Crohn's disease?
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P547: Rate of Colectomy Increases within Twelve Months of Sequential Therapy for Ulcerative Colitis
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P547: Safety and efficacy of vedolizumab in the treatment of patients with moderate to severe Ulcerative Colitis: a systematic review and meta-analysis
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P548 Efficacy, safety, and pharmacokinetics after switching from infliximab originator to biosimilar SB2 in inflammatory bowel disease patients: A long-term observational, prospective cohort study
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P548: Drug Survival in Patients with Inflammatory Bowel disease: An observational study
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P548: Efficacy outcomes of placebo maintenance treatment in patients with moderate to severe Crohn's disease who responded to placebo induction therapy: Post-hoc analysis of the Phase 3 ADVANCE, MOTIVATE, and FORTIFY Risankizumab Studies
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P548: External validation and consistency in time of patient segmentation based on disease acceptance and perceived control in Inflammatory Bowel Disease
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P548: Hepatitis B virus reactivation in hepatitis B virus infected patients with inflammatory bowel disease receiving anti-tumor necrosis factor-alpha therapy
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P548: Limited clinical value in assessing the distribution of endoscopic disease activity in patients with ulcerative colitis
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P548: Vedolizumab clinical decision support tool predicts hospitalisation, surgery, and healthcare resource utilisation
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P549 A virtual clinic enhances the quality use of anti-TNF dose intensification and rates of treatment success using a treat-to-target approach compared with standard outpatient care in Crohn’s disease
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P549: Changing Lanes: Switching Therapies in Inflammatory Bowel Disease, An Observational Study.
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P549: Effect of maintenance Ustekinumab on corticosteroid-free clinical outcomes in patients with Crohn's disease
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P549: One-Year Comparison of Clinical and Endoscopic Outcomes of Tofacitinib Versus Vedolizumab for Ulcerative Colitis After Anti-Tumor Necrosis Factor Failure: A Real-World Cohort Study in the United States
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P549: Oxidative stress and antioxidant capacity biomarkers in adults and children with IBD: current update from OxIBDiet trial
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P549: Systemic cytomegalovirus infection is a relevant factor affecting short- and long-term outcomes of patients with acute severe ulcerative colitis: An 11-year experience
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P549: Vitamin D deficiency as a part of extraintestinal manifestations in IBD Patients: a single-centre experience
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P550 Long-term effectiveness of anti-TNF agents in symptomatic stricturing Crohn’s disease
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM